Timothy Beukelman, Millie D Long, Rennie L Rhee, Michael D Kappelman, Peter A Merkel, William Benjamin Nowell, Cassie Clinton, Sarah Ringold, Vincent Del Gaizo, Brian Price, Dianne G Shaw, Shilpa Venkatachalam, David Cuthbertson, Fenglong Xie, Xian Zhang, Jeffrey R Curtis
BACKGROUND: The most reliable and meaningful approach for inclusion of patient-reported outcomes (PROs) in the evaluation of real-world clinical effectiveness of biologics in the treatment of autoimmune diseases is u ncertain. This study aimed to assess and compare the proportions of patients who had abnormalities in PROs measuring important general health domains at the initiation of treatment with biologics, as well as the effects of baseline abnormalities on subsequent improvement...
2023: Patient related Outcome Measures